Data Sheet (Cat.No.T4132)

TargetMol

BPTU

Chemical Properties



CAS No. : 870544-59-5

Formula: C23H22F3N3O3

Molecular Weight: 445.43

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	BPTU (BMS-646786) is an allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM). Non-nucleotide ligand. Binds receptor outside of the helical bundle. Blocks inhibition of spontaneous contraction of rat and mouse colon induced by electrical field stimulation, nicotine and P2Y agonists. Antithrombotic; reduces platelet aggregation.
Targets(IC50)	P2Y Receptor
In vivo	Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 μg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group. Octreotide-PPSG appears to inhibit the expression of SSTR2 and SSTR5 to a greater extent than that of Octreotide-soln treated group. A test dose of octreotide acetate significantly decreases the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetatea (5 mg intramuscular, q 4 wk) is initiated.

Solubility Information

Solubility	DMSO: 20 mg/mL (44.9 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.245 mL	11.2251 mL	22.4502 mL
5 mM	0.449 mL	2.245 mL	4.490 mL
10 mM	0.2245 mL	1.1225 mL	2.245 mL
50 mM	0.0449 mL	0.2245 mL	0.449 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Abrahamsen B, et al. Allosteric modulation of an excitatory amino acid transporter: the subtype-selective inhibitor UCPH-101 exerts sustained inhibition of EAAT1 through an intramonomeric site in the trimerization domain. J Neurosci. 2013 Jan 16;33(3):1068-87.
Zhao T V, Li Y, Liu X, et al. ATP release drives heightened immune responses associated with hypertension. Science immunology. 2019, 4(36): eaau6426.
Zhao T V, Li Y, Liu X, et al. ATP release drives heightened immune responses associated with hypertension[J]. Science immunology. 2019, 4(36): eaau6426.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481